PE64396A1 - INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN - Google Patents
INTERLEUKIN 1 RECEIVER ACCESSORY PROTEINInfo
- Publication number
- PE64396A1 PE64396A1 PE1996000031A PE00003196A PE64396A1 PE 64396 A1 PE64396 A1 PE 64396A1 PE 1996000031 A PE1996000031 A PE 1996000031A PE 00003196 A PE00003196 A PE 00003196A PE 64396 A1 PE64396 A1 PE 64396A1
- Authority
- PE
- Peru
- Prior art keywords
- accessory protein
- receptor
- polynucleotide
- same
- mentioned
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A: i) EL POLINUCLEOTIDO QUE COMPRENDE UNA SECUENCIA DE ADN SELECCIONADA DE: a) UN POLINUCLEOTIDO QUE TIENE LA SECUENCIA SEQ ID NO:1; b) UN POLINUCLEOTIDO QUE HIBRIDA CON EL ADN DE (a) EN CONDICIONES RESTRICTIVAS; c) UN POLINUCLEOTIDO QUE DIFIERE EN LA SECUENCIA DE CODONES DEBIDO A LA DEGENERACION DEL CODIGO GENETICO; QUE CODIFICA LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1, O UN FRAGMENTO ACTIVO DE LA MISMA; ii) A LA CELULA HOSPEDADORA QUE CONTIENE UN VECTOR DE EXPRESION O AL VECTOR QUE CONTIENE AL POLINUCLEOTIDO MENCIONADO; iii) A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 O UN FRAGMENTO ACTIVO DE LA MISMA, TAL COMO LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA, QUE ES CODIFICADA POR EL POLINUCLEOTIDO MENCIONADO; iV) UN ANTICUERPO MONOCLONAL QUE SE UNE ESPECIFICAMENTE A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA QUE IMPIDE LA ACTIVACION DEL COMPLEJO DEL RECEPTOR DE LA IL-1 MEDIENTE LA IL-1; V) EL PROCEDIMIENTO DE PREPARACION DE UNA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 QUE COMPRENDE: a) EXPRESION DE UN POLIPEPTIDO CODIFICADO POR UN ADN MENCIONADO EN UN HOSPEDERO ADECUADO; b) AISLAMIENTO DE DICHA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1; c) CONVERSION DE LA MISMA EN UN ANALOGO EN EL CUAL HAN SIDO MODIFICADOS GRUPOS SECUNDARIOS; Vi) PREPARACION DE UN ANTICUERPO DE LA PROTEINA ACCESORIAIT REFERS TO: i) THE POLYNUCLEOTIDE THAT INCLUDES A SELECTED DNA SEQUENCE OF: a) A POLYNUCLEOTIDE THAT HAS THE SEQ ID NO: 1; b) A POLYNUCLEOTIDE THAT HYBRIDIZES WITH THE DNA OF (a) UNDER RESTRICTIVE CONDITIONS; c) A POLYNUCLEOTIDE THAT DIFFERS IN THE SEQUENCE OF CODONS DUE TO THE DEGENERATION OF THE GENETIC CODE; THAT CODES THE ACCESSORY PROTEIN OF THE IL-1 RECEPTOR, OR AN ACTIVE FRAGMENT OF THE SAME; ii) THE HOSPITAL CELL CONTAINING A VECTOR OF EXPRESSION OR THE VECTOR CONTAINING THE MENTIONED POLYNUCLEOTIDE; iii) TO THE ACCESSORY PROTEIN OF THE IL-1 RECEPTOR OR AN ACTIVE FRAGMENT OF THE SAME, SUCH AS THE ACCESSORY PROTEIN OF THE HUMAN IL-1 RECEPTOR, WHICH IS CODED BY THE MENTIONED POLYNUCLEOTIDE; iV) A MONOCLONAL ANTIBODY THAT SPECIFICALLY Binds TO THE ACCESSORY PROTEIN OF THE HUMAN IL-1 RECEPTOR THAT PREVENTS THE ACTIVATION OF THE IL-1 RECEPTOR COMPLEX BY THE IL-1; V) THE PREPARATION PROCEDURE OF AN IL-1 RECEPTOR ACCESSORY PROTEIN THAT INCLUDES: a) EXPRESSION OF A POLYPEPTIDE CODED BY A DNA MENTIONED IN AN APPROPRIATE HOSPITAL; b) ISOLATION OF SUCH ACCESSORY PROTEIN FROM THE IL-1 RECEPTOR; c) CONVERSION OF THE SAME IN AN ANALOG IN WHICH SECONDARY GROUPS HAVE BEEN MODIFIED; Vi) PREPARATION OF AN ANTIBODY OF THE ACCESSORY PROTEIN
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37626895A | 1995-01-23 | 1995-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE64396A1 true PE64396A1 (en) | 1997-01-28 |
Family
ID=23484321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000031A PE64396A1 (en) | 1995-01-23 | 1996-01-15 | INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0808365A1 (en) |
| JP (1) | JPH10512453A (en) |
| AR (1) | AR003919A1 (en) |
| AU (1) | AU4537096A (en) |
| BR (1) | BR9606837A (en) |
| CA (1) | CA2210724A1 (en) |
| CO (1) | CO4480033A1 (en) |
| CZ (1) | CZ208197A3 (en) |
| EA (1) | EA199700265A1 (en) |
| FI (1) | FI973089A0 (en) |
| HU (1) | HUP9702458A2 (en) |
| IL (1) | IL116796A0 (en) |
| MX (1) | MX9705501A (en) |
| NO (1) | NO973404L (en) |
| PE (1) | PE64396A1 (en) |
| PL (1) | PL321538A1 (en) |
| TR (1) | TR199700652T1 (en) |
| WO (1) | WO1996023067A1 (en) |
| ZA (1) | ZA96333B (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7011696A (en) * | 1996-08-26 | 1998-03-19 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| ES2615357T3 (en) | 1996-12-06 | 2017-06-06 | Amgen Inc. | Combination therapy using an IL-1 inhibitor to treat IL-1 mediated diseases |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP0979282A1 (en) * | 1997-04-30 | 2000-02-16 | F. Hoffmann-La Roche Ag | Rat st38.2 chemokine |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| AU755391B2 (en) | 1997-12-23 | 2002-12-12 | Immunex Corporation | SIGIRR DNA and polypeptides |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
| GB2375604A (en) * | 2001-05-18 | 2002-11-20 | Warner Lambert Co | Methods for screening using interleukin soluble trimolecular complex |
| PL222211B1 (en) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Antibodies to opgl |
| KR100453877B1 (en) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR |
| AU2002324625B2 (en) * | 2001-08-07 | 2008-05-08 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
| AU2005231822B2 (en) | 2004-04-02 | 2011-07-21 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| WO2005105830A1 (en) * | 2004-05-05 | 2005-11-10 | Valorisation-Recherche, Societe En Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US20090048161A1 (en) * | 2005-05-05 | 2009-02-19 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| AR056806A1 (en) | 2005-11-14 | 2007-10-24 | Amgen Inc | RANKL- PTH / PTHRP ANTIBODY CHEMICAL MOLECULES |
| JP2011515497A (en) | 2008-03-26 | 2011-05-19 | セレラント セラピューティクス インコーポレイテッド | Immunoglobulins and / or Toll-like receptor proteins associated with myeloid hematological proliferative diseases and uses thereof |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| EP2665749B1 (en) * | 2011-01-19 | 2016-01-13 | Cantargia AB | Anti-il1rap antibodies and their use for treating solid tumours |
| WO2012177595A1 (en) * | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| CN115505042A (en) | 2015-06-26 | 2022-12-23 | 赛诺菲生物技术公司 | Monoclonal anti-IL-1 RACP antibodies |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CA3067637A1 (en) | 2017-06-20 | 2018-12-27 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free dna |
| TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2021236962A1 (en) | 2020-05-20 | 2021-11-25 | The Medical College Of Wisconsin, Inc. | Compositions and methods for inhibiting cytokine-release syndrome |
| CN114835799A (en) * | 2021-05-28 | 2022-08-02 | 百奥赛图江苏基因生物技术有限公司 | Construction method and application of IL1RAP gene humanized non-human animal |
-
1996
- 1996-01-15 PE PE1996000031A patent/PE64396A1/en not_active Application Discontinuation
- 1996-01-16 ZA ZA96333A patent/ZA96333B/en unknown
- 1996-01-17 EA EA199700265A patent/EA199700265A1/en unknown
- 1996-01-17 PL PL96321538A patent/PL321538A1/en unknown
- 1996-01-17 HU HU9702458A patent/HUP9702458A2/en unknown
- 1996-01-17 MX MX9705501A patent/MX9705501A/en unknown
- 1996-01-17 CZ CZ972081A patent/CZ208197A3/en unknown
- 1996-01-17 WO PCT/EP1996/000181 patent/WO1996023067A1/en not_active Application Discontinuation
- 1996-01-17 CA CA002210724A patent/CA2210724A1/en not_active Abandoned
- 1996-01-17 AU AU45370/96A patent/AU4537096A/en not_active Abandoned
- 1996-01-17 TR TR97/00652T patent/TR199700652T1/en unknown
- 1996-01-17 JP JP8522598A patent/JPH10512453A/en active Pending
- 1996-01-17 IL IL11679696A patent/IL116796A0/en unknown
- 1996-01-17 BR BR9606837A patent/BR9606837A/en unknown
- 1996-01-17 EP EP96901291A patent/EP0808365A1/en not_active Withdrawn
- 1996-01-19 AR ARP960101095A patent/AR003919A1/en unknown
- 1996-01-22 CO CO96002329A patent/CO4480033A1/en unknown
-
1997
- 1997-07-22 FI FI973089A patent/FI973089A0/en unknown
- 1997-07-23 NO NO973404A patent/NO973404L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA96333B (en) | 1996-07-23 |
| JPH10512453A (en) | 1998-12-02 |
| HUP9702458A2 (en) | 1998-04-28 |
| WO1996023067A1 (en) | 1996-08-01 |
| CZ208197A3 (en) | 1997-11-12 |
| CA2210724A1 (en) | 1996-08-01 |
| NO973404D0 (en) | 1997-07-23 |
| PL321538A1 (en) | 1997-12-08 |
| FI973089A (en) | 1997-07-22 |
| AR003919A1 (en) | 1998-09-30 |
| EA199700265A1 (en) | 1998-04-30 |
| AU4537096A (en) | 1996-08-14 |
| NO973404L (en) | 1997-07-23 |
| CO4480033A1 (en) | 1997-07-09 |
| IL116796A0 (en) | 1996-05-14 |
| TR199700652T1 (en) | 1998-02-21 |
| FI973089A0 (en) | 1997-07-22 |
| MX9705501A (en) | 1997-10-31 |
| BR9606837A (en) | 1998-05-26 |
| EP0808365A1 (en) | 1997-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE64396A1 (en) | INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN | |
| AR248044A1 (en) | Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. | |
| FI100056B (en) | Expression of human proapolipoprotein A-I | |
| ATE136908T1 (en) | PEPTIDES AND ANTIBODIES THAT INHIBIT INTEGRIN LIGAND BINDING | |
| CA2096159A1 (en) | Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates | |
| IL86278A (en) | Endowing cells with antibody specificity using chimeric t cell receptor | |
| ES2054601T3 (en) | PROTEIN WITH CYTOKINE TYPE ACTIVITY, RECOMBINANT DNA CODE FOR THIS PROTEIN, CELLS AND TRANSFORMED MICROORGANISMS. | |
| IL98024A0 (en) | Cd44-surface proteins,dna-sequences coding therefor,polypeptides coded by said dna sequences and diagnostic compositions containing the same | |
| Porter | The structure of the heavy chain of immunoglobulin and its relevance to the nature of the antibody-combining site. The Second CIBA Medal Lecture. | |
| FI941048A (en) | DNA sequences encoding gelonin polypeptide | |
| BR9500271B1 (en) | recombinant DNA sequence, vector, transformed prokaryotic and fungal cells, and protein with sucrose-isomerase activity and with platinase and / or trehalulase activity. | |
| EA201001190A1 (en) | ISOLATED ANTIBODY, SPECIFICALLY ASSOCIATED WITH POLYPEPTIDE, CONTAINING FROM THE SEQUENCE OF AMINO ACID RESIDUES | |
| DK1417222T3 (en) | Isolated polypeptides based on the neutralizing epitope of the p17 protein from HIV suitable for vaccines as well as neutralizing anti-p17 antibodies that specifically recognize said neutralizing epitope | |
| NO975565L (en) | Leg stimulating factor | |
| IL75553A (en) | Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto | |
| Sherman et al. | Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia | |
| DE60031414D1 (en) | UNIQUE POLYPEPTIDES CONTAINING N-TERMINAL TROPONIN I FRAGMENTS AND TROPONIN C | |
| AR025482A1 (en) | DNA SEQUENCE CODING A PROTEIN ABLE TO BIND TRAF; VECTOR UNDERSTANDING SUCH SEQUENCE; GUEST CELLS TRANSFORMED WITH SUCH VECTOR; PROTEINS IREN CODED BY SUCH SEQUENCE; METHOD FOR PRODUCING THE PROTEIN; SPECIFIC ANTIBODIES FOR SUCH PROTEINS; METHOD FOR M | |
| DE69132874T2 (en) | A RECOMBINANT GENE ENCODING A PROTEIN WITH ENDOCHITINASE ACTIVITY | |
| NZ508812A (en) | Peptides for the prevention or treatment of HIV | |
| US6319890B1 (en) | Inhibition of binding of complement Factor H | |
| Leone et al. | Characterisation of an epitope recognised by a monoclonal antibody against horse alcohol dehydrogenase using peptides synthesised on solid support | |
| FR2829774B1 (en) | N-DESOXYRIBOSYLTRANSFERASES OF LACTOBACILLES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR APPLICATIONS | |
| Ohno | The cardinal principle of like attracting like generates many ubiquitous oligopeptides shared by divergent proteins | |
| CHERSI et al. | Short synthetic peptides derived from viral proteins compete with HIV gp120 for the binding to CD4 receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |